Regeneron inks drug pricing deal with Trump, will offer hearing-loss therapy for free
CNBC • • general
Key Points:
- Regeneron has agreed to lower drug prices for some Americans as part of a deal with President Donald Trump's administration, which aims to tie U.S. drug prices to the lowest prices in other developed countries.
- The company will provide its newly approved hearing-loss gene therapy, Otarmeni, for free to eligible U.S. patients following FDA approval.
- Otarmeni, approved under the FDA's National Priority Voucher program, treats an ultra-rare genetic condition causing hearing loss and represents a significant advancement beyond cochlear implants.
- The agreement exempts Regeneron from tariffs, including potential 100% levies on pharmaceuticals, for three years, similar to deals made with 17 other biotech and pharma companies under the Trump administration.
- Analysts project that Otarmeni could achieve peak sales of $130 million, highlighting its commercial potential despite serving a small patient population.
